Alvogen builds $250m biosimilars plant in Iceland
This article was originally published in Scrip
Executive Summary
Alvotech, an Iceland-based sister company of the privately owned US generics firm Alvogen, is to invest $250m in a biosimilars development and manufacturing facility in Reykjavik, Iceland. The plant will produce biosimilar monoclonal antibodies for marketing by Alvogen, which currently markets biosimilars in some parts of the world through alliances with other firms, including Hospira.
You may also be interested in...
Asia Deal Watch: Alvotech Signs On To Biosimilar Manufacturing JV In China
With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.
INTERVIEW: Robert Wessman On Growing Generics, And Why Biosimilars Will Dominate The Future
Robert Wessman, executive chairman of the rapidly growing generics company Alvogen, talks about the future of the generics industry, how to build a global generics company, and founding the Icelandic biosimilars manufacturer, Alvotech.
INTERVIEW: Robert Wessman On Growing Generics, And Why Biosimilars Will Dominate The Future
Robert Wessman, executive chairman of the rapidly growing generics company Alvogen, talks about the future of the generics industry, how to build a global generics company, and founding the Icelandic biosimilars manufacturer, Alvotech.